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OBJECTIVE: It has been shown that SOCS-1 plays an important role in the proper control of cytokine/growth
factor responses and acts as a tumor suppressor in acute myeloid leukemias. Therefore, the objective of the
present study was to evaluate the in vitro effect of treatment with Nutlin-3, a small molecule inhibitor of the
MDM2/p53 interaction, on the expression of the suppressor of cytokine signaling 1 in primary acute myeloid
leukemia cells and in myeloid cell lines with differential p53 status.
METHOD: The expression of the suppressor of cytokine signaling 1 was quantitatively analyzed by real-time PCR in
myeloid p53wild-type (OCI and MOLM) and p53null HL-60, leukemic cell lines, in patient-derived acute myeloid
leukemia blasts, and in primary normal cell types, such as macrophages, endothelial cells, and bone marrow
mesenchymal stem cells. The p53-dependence of the suppressor of cytokine signaling 1 upregulation that is induced
by Nutlin-3 was analyzed in experiments performed using siRNA for p53, while the functional upregulation of the
suppressor of cytokine signaling 1 was analyzed by assessing the levels of phosphorylated STAT-3.
RESULTS:Nutlin-3 significantly upregulated the transcription of the suppressor of cytokine signaling 1 in p53wild-type
OCI and MOLM but not in p53deleted p53null HL60, myeloid leukemic cell lines, as well as in primary acute myeloid
leukemia blasts. Conversely, and somewhat unexpectedly, Nutlin-3 did not modulate the suppressor of cytokine
signaling 1 expression in primary normalmacrophages, endothelial cells, and bonemarrowmesenchymal stem cells.
The p53-dependent upregulation of the suppressor of cytokine signaling 1 by Nutlin-3 was associated with the
downregulation of phosphorylated STAT-3, a major molecular target of the suppressor of cytokine signaling 1.
CONCLUSION: Overall, our data suggest a potential role for the suppressor of cytokine signaling 1 as a therapeutic
target of Nutlin-3 in p53 wild-type acute myeloid leukemias.
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& INTRODUCTION
The selective small molecule inhibitor Nutlin-3 binds
MDM2 in the p53 binding pocket with high selectivity and
can release p53 from negative control, leading to an effective
stabilization of p53 and activation of the p53 pathway (1). A
number of studies have demonstrated that Nutlin-3 induces ex
vivo cytotoxic cell death of p53wild-type acute myeloid leuke-
mias (AMLs) (2–7), and Nutlin-3 was recently shown to
upregulate the suppressor of cytokine signaling 1 (SOCS-1) in
primary B leukemic cells through the mirR-155 pathway (8,9).
Since the cloning of SOCS-1, it has become evident that the
SOCS proteins are important for the proper control of cytokine
and growth factor responses, and the absence of SOCS
proteins leads to excessive cytokine signaling (10). In addition,
SOCS-1 also acts as a tumor suppressor, as documented by the
fact that SOCS-1 silencing by DNA hypermethylation at the
gene promoter region has been found in both solid tumors,
such as hepatocarcinomas (11), and AMLs (12–17).
Based on these findings, in the present study, we
evaluated the effect of Nutlin-3 treatment on SOCS-1
expression in primary AML cells, as well as in myeloid cell
lines with differential p53 status. Additionally, the effect of
Nutlin-3 exposure on SOCS-1 expression was evaluated in
primary normal cells characteristic of the bone marrow
microenvironment, such as primary macrophages, endothe-
lial cells, and multipotent stromal cells (MSCs).
& MATERIALS AND METHODS
Cell culture
The myeloid p53wild-type (OCI and MOLM) and p53null
(HL-60) leukemic cell lines were purchased from the ATCC
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(American Type Culture Collection, Manassas, VA). MOLM
and HL-60 leukemic cell lines were cultured in RPMI-1640
containing 10% FBS (both from Gibco BRL, Grand Island,
NY), while OCI cells were cultured in alpha-MEM (LONZA,
Basel, Switzerland) containing 10% FBS, as previously
described (18).
Primary peripheral blood samples were collected in heparin-
coated tubes from five AML patients and six healthy blood
donors after informed consent was obtained in accordance with
the Declaration of Helsinki and in agreement with institutional
guidelines. Peripheral blood mononuclear cells (PBMC) from
AML patients and healthy donors were isolated by gradient
centrifugation with lymphocyte cell separation medium
(Cedarlane Laboratories, Hornby, ON). The percentage of
blasts among leukemic PBMC ranged from 60–85% for all
patients, as assessed by light microscopy and verified by
standard flow cytometry analysis. AML patient cells were
seeded at a density of 16106 cells/ml in RPMI containing 10%
FBS (both from Gibco BRL). To obtain primary normal adherent
macrophages, blood donor PBMCs were seeded at a density of
56106 cells/ml, and non-adherent cells were removed after 18
hours. Adherent cells were cultivated in fresh RPMI medium
containing 10% FBS, as previously described (19).
Human umbilical vein endothelial cells (HUVECs) were
purchased from BioWhittaker (Walkersville, MD) and
grown on 0.2% gelatin-coated tissue culture plates in
M199 endothelial growth medium supplemented with 20%
FBS, heparin, and 50 mg/ml ECGF (all from BioWhittaker),
as previously described (20). In all experiments, cells were
used between the 3rd and 5th passage in vitro. Bone marrow-
derived MSCs were purchased from LONZA and grown in
MSC Growth Medium (MSC-GM, LONZA), as previously
described (21,22).
Culture treatments and evaluation of cell
cytotoxicity
Cells were treated by adding Nutlin-3 (10 mM; obtained
from Cayman Chemical, Ann Arbor, MI) to the culture
medium. After treatment, cell viability was monitored up to
48 hours by Trypan blue dye exclusion, as previously
described (23). In parallel, the degree of apoptosis was
quantified by Annexin V-FITC/propidium iodide (PI)
staining (Immunotech, Marseille, France) followed by flow
cytometry analysis, as previously described (24,25). To
analyze the cell cycle profile, cells were incubated with
50 mM 5-bromodeoxyuridine (BrdU; Sigma Aldrich) at 37 C˚
for 1 hour, the anti-BrdU antibody (BD Biosciences
Pharmingen, Franklin Lakes, NJ) was bound to BrdU, and
the complex was detected by an FITC-conjugated secondary
antibody (Beckman-Coulter, Marseille, France) (26,27). After
additional staining with 50 mg/ml PI (Sigma-Aldrich), the
cell samples were analyzed by flow cytometry.
RNA analysis
Aliquots of untreated and Nutlin-3-treated cells were
harvested for RNA extraction 24–48 hours post-treatment.
Total RNA was extracted using the Qiagen RNeasy Plus
mini kit (Qiagen, Hilden, Germany) according to the
supplier’s instructions. The integrity of the total RNA
preparation was assessed using an Agilent 2100
Bioanalyzer. RNA was transcribed into cDNA using the
GEArray AmpoLabeling-LPR Kit (Superarray Bioscience
Corporation, Frederick, MD). Investigations of SOCS-1 and
miR-155 gene expression were both carried out in RNA
samples with the real-time thermal analyzer Rotor-GeneTM
6000 (Corbett, Cambridge, UK) using SYBR Green-based
technology and the RT-PCR primer set for human SOCS-1
cDNA or miR-155 (SABioscience, Frederick, MD). Gene
expression of the target sequences was normalized with
respect to the expression of endogenous controls. Each
sample was tested in triplicate.
Western blot analyses
Cells were lysed in ice-cold RIPA buffer (50 mM Tris pH
7.5, 150 mM NaCl, 0.1% SDS, 1% Nonidet P-40, 0.25%
sodium desoxycholate) supplemented with protease inhibi-
tors (Complete, Roche; Germany) on ice for 1 hour (28).
Before gel migration, samples were added to loading buffer
(250 mM Tris pH 6.8, 2% SDS, 40% glycerin, 20% beta-
mercaptoethanol) and boiled for 2 minutes. Equal amounts
of protein for each sample were migrated in acrylamide gels
and blotted onto nitrocellulose filters, as previously
described (29), before incubation with the following mono-
clonal antibodies: anti-p53, anti-SOCS-1, anti-STAT-3, and
anti-phospho-STAT-3 (all from Santa Cruz Biotechnology,
Santa Cruz, CA), as well as anti-tubulin (Sigma-Aldrich).
After incubation with peroxidase-conjugated anti-mouse
IgG, specific reactions were revealed with the ECL detection
kit (Amersham Pharmacia Biotech).
Multiplex immunoassay
The MILLIPLEX MAP Human Multi-Pathway 9-plex
Magnetic Bead Signaling kit phosphoprotein (Merck
Millipore, Billerica, MA, USA) was used to detect changes
in phosphorylated ERK/MAP kinase 1/2, Akt, STAT-3,
JNK, p70 S6 kinase, NF-kB, STAT-5A/B, CREB, and p38 in
cell lysates using the Luminex system, according to the
manufacturer’s instructions. Briefly, cells were seeded at a
density of 16106/ml and treated with Nutlin-3 (10 mM). At
different time points, cells were harvested in MILLIPLEX
MAP lysis buffer (Merck Millipore) in the presence of the
Protease Inhibitor Cocktail Set III (Calbiochem, San Diego,
CA). Each lysate was diluted in the MILLIPLEX MAP Assay
Buffer 2 (Merck Millipore), incubated at 4 C˚ overnight, and
analyzed according to the assay protocol. Median
Fluorescence Intensity (MFI) was measured with the
Luminex System and normalized for mg of protein.
Transfection experiments
OCI cells (1.256106) were resuspended in 0.1 ml of
NucleofectorTM solution V from the human Nucleofector
kit V (Amaxa, Cologne, Germany). Two mg of plasmid DNA
(GFP-construct) or 1 mg of siRNA was mixed with the 0.1 ml
of cell suspension, transferred into a 2.0-mm electroporation
cuvette, and nucleofected using an Amaxa Nucleofector II
apparatus, following the manufacturer’s guidelines and as
previously described (30). After transfection, cells were
immediately transferred into complete medium and cul-
tured in six-well plates at 37 C˚. Transfection efficiency was
estimated in each experiment by scoring the number of
GFP-positive cells by flow cytometry analysis. siRNAs were
designed and manufactured by Ambion Inc. (Austin, TX)
according to the current guidelines for effective gene knock-
down by this method and were validated in preliminary
experiments. Negative control siRNA, comprised of a 19-bp
scrambled sequence with 39 dT overhangs (Ambion’s
Silencer negative control siRNA), was used to demonstrate
that transfection did not induce non-specific effects on gene
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expression. In miR-155 functional studies, cells were
transfected with the hsa-miR-155 anti-miR oligo to inhibit
the activity of endogenous miR-155. In parallel, cells were
transfected with the FAM-labeled miR negative control
oligo as a non-targeting negative control and to monitor
transfection efficiency. All oligos were obtained from
Ambion.
Statistical analysis
Descriptive statistical analyses were conducted. For each
set of experiments, values are reported as the mean¡SD.
Data were analyzed with Student’s t test, and statistical
significance was defined as p,0.05.
& RESULTS
Upregulation of SOCS-1 expression in p53wild-type
AML cells by Nutlin-3
In the first group of experiments, we investigated whether
Nutlin-3 affected the expression of SOCS-1 mRNA in AML
cells. For this purpose, we assessed both patient (n = 5) AML
blasts and myeloid cell lines, characterized by either p53wild-type
(OCI and MOLM) or p53null (HL-60) status. As reported in
Table 1, Nutlin-3 induced significant cytotoxicity in all patient
AML blast cultures and p53wild-type myeloid cell lines but not in
p53null HL-60 cells, which is consistent with the ability of
Nutlin-3 to induce apoptosis and cell cycle arrest (2,4).
Moreover, as shown in Figure 1A, treatment with Nutlin-3
induced a significant (p,0.05) increase in SOCS-1 mRNA levels
in all primary AML blasts and in p53wild-type OCI and MOLM
cells but not in p53null HL-60 cells. In an attempt to also evaluate
SOCS-1 protein, we analyzed cell lysates by the Western blot
assay. However, under our experimental conditions, the
commercially available antibodies did not allow for clear and
reproducible protein detection (data not shown). The data
shown in Figure 1A suggest but do not prove that the Nutlin-3-
mediated upregulation of SOCS-1 in leukemic cells requires a
functional p53 pathway. Therefore, to ascertain the role of p53
in Nutlin-3-induced upregulation of SOCS-1, we used pre-
determined optimal experimental conditions to transfect siRNA
against p53 in OCI cells to specifically knock down p53 gene
expression. As shown in Figure 1B, p53 knock down counter-
acted the ability of Nutlin-3 to increase the level of p53 protein
in OCI cells and significantly (p,0.05) counteracted the ability
of Nutlin-3 to upregulate SOCS-1 expression. These data
demonstrate that the ability of Nutlin-3 to transcriptionally
upregulate SOCS-1 expression in myeloid leukemic cells is
dependent on p53.
The recent data demonstrating that Nutlin-3 downregu-
lates miR-155 in primary B-CLL (8), along with a key role for
miR-155 in regulating SOCS-1 expression (9,31,32), together
supported the investigation of miR-155 knock down on
SOCS-1 expression in response to Nutlin-3 in AML cell
models. For this purpose, OCI cells were transfected either
with the hsa-miR-155 anti-miR oligo to inhibit the activity of
endogenous miR-155 or with the miR negative control oligo
before exposure to Nutlin-3. Treatment with Nutlin-3
increased the levels of SOCS-1 mRNA in control (miR
negative control oligo) transfected cells, and this effect was
enhanced in cells transfected with anti-miR-155 (Figure 1C).
Although these experiments did not address a potential
direct link between Nutlin-3 and miR-155, which also acts as
oncomiR in AML (33,34), they confirm an important role for
miR-155 in SOCS-1 transcriptional modulation and show
that anti-miR-155 enhances the ability of Nutlin-3 to
upregulate SOCS-1 mRNA expression in AML cells.
Because SOCS-1 is known to affect the intracellular
signaling pathways downstream of several cytokines and
one of its major targets is represented by the inhibition of
the JAK/STAT-3 pathway (10,11), we analyzed the func-
tionality of Nutlin-3-mediated induction of SOCS-1 by
assessing the levels of phosphorylated STAT-3. For this
purpose, leukemic cells were exposed to Nutlin-3 (10 mM),
and at different time points, the phosphorylation pattern of
the main intracellular pathways was evaluated by a multi-
plex assay. Among the activated pathways (Figure 2),
phosphorylation levels of both ERK1/2 and p38, although
characterized by different baseline kinetics, were unaffected
by Nutlin-3 exposure (Figure 2A). Of interest, STAT-3
phosphorylation, characterized by a progressive increase
over time in untreated cultures, was significantly inhibited
after 24 hours of Nutlin-3 treatment, as further confirmed by
Western blot analysis (Figure 2B). Overall, these results are
consistent with those of a previous study showing that
ERK1/2 is not affected by SOCS-1 (35), and they validate the
ability of SOCS-1 to downregulate the JAK/STAT-3 path-
way upon Nutlin-3 treatment of leukemic cells.
Lack of SOCS-1 modulation by Nutlin-3 in primary
normal macrophages, endothelial cells, and MSC
Because SOCS-1 plays a role in different cell types (10), we
analyzed whether Nutlin-3 was able to also modulate SOCS-
1 in primary normal cells, such as normal macrophages,
endothelial cells, and bone marrow MSCs, which represent
the relevant cytotypes present in the bone marrow micro-
environment. As shown in Figure 3, Nutlin-3 did not
significantly modulate SOCS-1 expression in any of the
primary cell types investigated, suggesting that the ability of
Nutlin-3 to upregulate SOCS-1 was confined to p53wild-type
malignant AML cells (Figure 3).
& DISCUSSION
Previous findings indicated that SOCS-1 may function as a
tumor suppressor and that it is frequently found to be
silenced in hematopoietic malignancies. In this context, we
have demonstrated that a novel non-genotoxic activator of
the p53 pathway, Nutlin-3, is able to significantly upregulate
SOCS-1 expression in primary AML blasts as well as in
p53wild-type myeloid OCI and MOLM cell lines, but not in
Table 1 - Effect of Nutlin-3 treatment on myeloid
leukemic cell viability.
Myeloid
leukemic cells
Cell viability of Nutlin-3 treated
cultures (% of untreated cultures)a
OCI 30¡7
MOLM 6¡3
HL60 88¡10
Pt. 1 23¡6
Pt. 2 29¡8
Pt. 3 36¡9
Pt. 4 22¡5
Pt. 5 32¡6
aLeukemic cells were exposed to Nutlin-3 (10 mM) and cell viability was
analysed at 48 hours of treatment. Data are reported as means¡SD of at
least three independent experiments.
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p53null HL-60 cells. In addition, we have demonstrated that
the upregulation of SOCS-1 was functional because this
upregulation resulted in a significant downregulation of
STAT-3 phosphorylation levels. It is important to note that
the activation of STAT-3 has been frequently reported in both
primary human acute leukemia and leukemic cell lines (36),
Figure 1 - Transcriptional upregulation of SOCS-1 by Nutlin-3 in AML cells. InA, AML cell lines and primary AML patient (Pt.) cells were exposed
to Nutlin-3 (10 mM). Levels of SOCS-1mRNA were analyzed by quantitative RT-PCR. The results are expressed as the fold of increase in SOCS-1
modulation by Nutlin-3 after 24 hours of treatmentwith respect to the control untreated cultures (set to 1) (hatched line). Data are reported as
the mean¡SD of the results from at least three experiments, each performed in triplicate. In B, OCI cells were transfected with control
scrambled (scr.) siRNA or p53 siRNA before treatment with Nutlin-3. p53 protein levels were analyzed by Western blot, and tubulin staining is
shown as the loading control. Representative examples of Western blot results, from three independent experiments are shown. In parallel,
levels of SOCS-1mRNAwere expressed as the fold increasewith respect to the scrambled control transfected cultures. In C, OCI cells transfected
with either hsa-miR-155 anti-miR oligo or miR negative control oligo were exposed to Nutlin-3 and SOCS-1 mRNA was expressed as the fold
increase in modulation. Asterisks, p,0.05 with respect to the untreated cultures or to the scrambled control transfected cultures.
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as well as that STAT-3 represents a major molecular target of
SOCS-1 (10,11). However, no modulation of SOCS-1 was
observed in primary normal macrophages, endothelial cells,
or bone marrow MSC, suggesting that Nutlin-3 selectively
upregulated SOCS-1 in malignant cells but not in normal cells
of the bone marrow microenvironment. To date, we do not
have an explanation for this differential activity of Nutlin-3 in
myeloid leukemia cells and primary normal cells. We cannot
exclude the possibility that Nutlin-3-mediated upregulation
of SOCS-1 is also dependent on its ability to arrest cell cycle
progression in highly cycling malignant cells, as some
experimental observations (generated by blocking the cell
cycle with different pharmacological agents) potentially
support this hypothesis. However, these data are still too
preliminary to draw any major conclusions. Additionally,
a cycle-related effect of Nutlin-3 in upregulating SOCS-1
was also suggested by the more robust SOCS-1 induction
in leukemic cell lines (3- to 8-fold) compared with
primary AML (2- to 4-fold), a result also previously
reported for primary B-CLL cells (2- to 4-fold; 9). Thus,
further investigation is clearly needed to elucidate the
molecular mechanisms underlining the differential beha-
vior of Nutlin-3 with respect to SOCS-1 induction in
normal cells compared with malignant cells.
A second interesting finding of our study was the
identification that the Nutlin-3-mediated upregulation of
SOCS-1 was potentiated by a concomitant downregulation
of miR-155, which is known to act as an oncomiR in AML
(33,34). Thus, SOCS-1 represents a potential common target
between Nutlin-3 and antago-miR-155.
In conclusion, our data demonstrate that Nutlin-3, a small
molecule with great therapeutic potential in hematological
malignancies (37,38), upregulates the SOCS-1 pathway in
leukemic cells but apparently not in normal quiescent cells.
Figure 2 - Phosphorylation patterns of Nutlin-3-treated AML cells. Leukemic cells were exposed to Nutlin-3 (10 mM), and
phosphoprotein levels were analyzed in cell lysates by the Multiplex assay at the indicated time points. Phosphoprotein levels are
expressed as the median fluorescence intensity (MFI). Data are reported as the mean¡SD. In A, phosphorylation levels of ERK1/2 and
p38 in untreated and Nutlin-3-treated cultures are shown. In B, phosphorylation levels of STAT-3 in untreated and Nutlin-3-treated
cultures, analyzed with the Multiplex assay and validated by Western blot analysis, are shown. Asterisks, p,0.05 with respect to the
untreated cultures.
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Due to the role of SOCS-1 as an oncosuppressor, therapeutic
combinations based on Nutlin-3 warrant further investiga-
tions with regard to the treatment of AML.
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